Previous Article | Next Article ![]()
Infection and Immunity, July 2000, p. 3822-3829, Vol. 68, No. 7
Department of Pathology, University of
Geneva, Geneva CH 1211,1 and Institute
of Biochemistry, World Health Organization IRTC, 1066 Epalinges,2 Switzerland; Amgen, Inc.,
Thousand Oaks, California 91320-17893; and
CNRS-UPRES A6020, Université de la
Méditerranée, 13385 Marseille, France4
Received 8 July 1999/Returned for modification 30 November
1999/Accepted 28 March 2000
We explored the role of urokinase and tissue-type plasminogen
activators (uPA and tPA), as well as the uPA receptor (uPAR; CD87) in
mouse severe malaria (SM), using genetically deficient ( In mice, infection by
Plasmodium bergei ANKA leads, in susceptible mouse strains,
to a lethal syndrome, commonly known as cerebral or severe malaria
(SM), in which mice die 7 to 9 days after infection in a state of coma
associated with neurological manifestations; (51; reviewed in reference
49). Prominent in this syndrome are a breakdown of
the blood-brain barrier, microhemorrhages, and sequestration of
macrophages in the cortical venules (6, 12, 46). In
addition, there is a sequestration of macrophages, polymorphonuclear
neutrophils (PMNs), parasitized red blood cells (pRBC), and platelets
in other organs, notably the lung (12, 46). Hence, since
this syndrome is not limited to the brain, it is also referred to as
SM. Various studies using antibodies, recombinant cytokines or knockout
mice have shown that the secretion of tumor necrosis factor (TNF) is an
important effector of the mortality of SM (15, 20, 43).
In humans, acute phase of malaria infection can also result in severe
complications, leading eventually to death, with symptoms ranging from
respiratory distress up to coma (reviewed in references 49 and 50). Especially in
children, Plasmodium falciparum infection can manifest
itself as a coma, associated with neurological dysfunctions resembling
ANKA infection in susceptible mice. The pathogenesis of coma is poorly
understood and might be different in humans and mice since in humans
cerebral dysfunction is associated with the sequestration of RBC or
pRBC within the brain capillaries, while during ANKA-induced coma in
mice, pRBC sequestration is not evident in the brain but is important
in the lungs (7, 12, 28). Coma occurring in mice is
generally attributed to the sequestration of macrophages within the
cortical venules, an alteration also observed during human SM
(36). The sequestration of pRBC within the microcirculation
might be critical for the severity of the disease in either species
since they might release a glycosylphosphatidylinositol toxin
(44) or, alternatively, they might obstruct the capillary
circulation (28). Breakdown of the blood-brain barrier is
evident during SM, but its pathogenesis or role in the coma in either
species is not established. Microhemorrhages have also been reported in
the brain and elsewhere in both human and mouse SM (46). SM,
even with predominant neurological symptoms, is a systemic disease,
with associated dysfunctions of the major organs. Involvement of the
lung is evident during "cerebral malaria" in humans as in mice and
is associated with the sequestration of macrophages, neutrophils,
platelets, and pRBC in the alveolar capillaries (5, 7, 10, 12,
28). Thrombocytopenia, due to a reduced platelet life span is
common to SM in both mice and humans and is not associated with
coagulopathy (21, 45, 49). Finally, the essential role of
TNF in the mortality appears to be similar in both species since a
strong correlation has been documented between TNF production and the
lethality of malaria in humans (22, 31).
TNF production is induced by an immune response elicited by the
presence of the parasite in the blood (19). Indeed,
depletion of CD4 T lymphocytes or administration of cyclosporin
prevents the acute mortality of ANKA infection in mice, apparently by
decreasing TNF production (17, 19, 49). TNF might be
responsible for some of the manifestations of SM such as hypoglycemia
and the increase of the expression of adhesion molecules. Indeed, TNF induces an upregulation of adhesion molecules on endothelia, notably of
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion
molecule 1 (VCAM-1) (26, 27), which might increase the
adhesion of leukocytes and other cells and thereby disturb the
microcirculation in the brain and other organs. This pathogenic hypothesis is supported by the delayed mortality seen in mice treated
with anti-CD11a monoclonal antibody (MAb; LFA-1, a
In the present report, we took advantage of mice genetically deficient
in the uPA or uPAR genes to explore the contribution of this system to
the mortality and sequestration of various cell types induced by ANKA
infection. The results indicate that the severity of malaria is
attenuated in uPA- and uPAR-deficient mice.
Mice.
uPA P. berghei ANKA infection.
The ANKA strain has
been passaged in rodents for decades (1). Mice were injected
intraperitoneally (i.p.) with 106 pRBC as described
previously (19). More recently, mice were also infected by
an intravenous (i.v.) injection of 5 × 104 pRBC. This
latter type of infection, which bypasses the peritoneal macrophages,
results in a parasitemia and mortality similar to the i.p. infection
but with less variability.
Treatment with aprotinin.
Aprotinin was purchased from Sigma
Chemical (St. Louis, Mo.), and 500 µg was injected i.v.
Blood collection.
Blood (0.015 ml) was isolated from the
retroorbital plexus of ethrane-anesthetized mice by using heparinized
capillaries and then diluted in EDTA (1%, final) in accordance with
the Swiss national guidelines. Blood elements were counted in a cell
counter (Casy 1; Schärfe, Reutlingen, Germany). To count the
parasitemia, a smear was prepared, dried, fixed in methanol, and
stained with May-Grünwald Giemsa.
Light and electron microscopy.
Mice were sacrificed via an
i.p. injection of pentobarbital sodium (Nembutal). The aorta was cut,
the thorax opened, and the lung was fixed by intratracheal instillation
of glutaraldehyde and processed for embedding in Epon. A section was
taken in the left lobe, across the hilus. Thin sections were prepared
from two blocks taken from the parenchyma per mouse. Thin sections were
examined with a Philips 400 electron microscope at 60 kV. Cells within
alveolar capillaries were examined, and the RBC, platelets, and PMNs
were counted. RBC were used as a neutral indicator of blood stasis, and
sequestration was evaluated by determining the platelet/RBC and PMN/RBC ratios.
Assessment of vascular leak.
Mice (three wild type and three
mutant) were injected i.v. with 0.2 ml of 1% Evans Blue on day 6, shortly before the death of the wild-type mice. After 1 h, mice
were sacrificed, and the staining of brain sections was assessed as an
indicator of increased capillary permeability. The vascular leak was
also assessed by the injection of labeled fibrinogen (see below).
Fibrinogen half-life and distribution.
Human
125I-labeled fibrinogen was purchased from Amersham (Little
Chalfont, United Kingdom). Ca. 105 cpm were injected i.v.
To evaluate fibrinogen turnover, 0.05 ml of blood was withdrawn form
the retroorbital sinus in a calibrated and heparinized capillary and
then counted in a gamma counter (Packard).
Platelet isolation and 51Cr labeling.
Donor mice
were pretreated with heparin (5 U, given intramuscularly), and blood
was withdrawn from the retroorbital plexus, using heparinized
capillaries, and collected in EDTA (1% final concentration in NaCl
[pH 7.0]) and separated by differential centrifugations
(30). The preparation was examined in a hemocytometer to
evaluate leukocyte or RBC contaminants, which were always below 10 Evaluation of TNF production.
TNF mRNA levels were evaluated
on Northern blots prepared from the lung, brain, and spleen RNA as
described previously (37). Quantification of TNF mRNA was
performed by PhosphorImager analysis (Molecular Dynamics, Inc.,
Sunnywale, Calif.), and the amount was normalized to the 18S RNA level
(1). The TNF serum level was assayed by using the InnoBasics
10m TNF ELISA kit (Innogenetics), which detects both free and
receptor-bound TNF with a sensitivity of 12 pg/ml.
Immunohistochemistry.
Frozen tissue sections were
immunostained as described elsewhere. Briefly, 5-µm sections were
incubated overnight at 4°C with a rat MAb directed against murine
GPIIb/IIIa (CD41, CD61, and MWReg30 immunoglobulin G1 [IgG1];
Pharmingen, San Diego, Calif.) (34). After a washing, the
sections were incubated 1 h at room temperature with biotinylated
goat anti-rat IgG (Southern Biotechnology, Bioreba, Reinach,
Switzerland) followed by the addition of horseradish peroxidase-avidin.
A color reaction was obtained with the addition of AEC
substrate-chromogen (Dako, Zug, Switzerland). Samples were analyzed on
a Zeiss Axiophot microscope using SAMBA quantitative image analysis
software (Faculty of Medicine, Université de la Méditerranée). Results were expressed as arbitrary units
(AU) of stained surface per square millimeter of lumen surface, as determined by planimetry. Leukocytes were counted as nucleated elements
(stained with hemalun) within an identified blood vessel.
Statistical evaluation.
Significance analysis of survival
curves was determined by using the Fisher's exact test. Groups of
values were compared using the nonparametric Mann-Whitney U test
(29).
Effect of uPA, tPA, and uPAR on the mortality associated with
SM.
Infection of +/+ mice resulted in an acute mortality, reaching
frequently 90%, by 8 to 9 days after injection as reported previously
(15). Mortality was significantly delayed in
uPA
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Delayed Mortality and Attenuated Thrombocytopenia
Associated with Severe Malaria in Urokinase- and Urokinase
Receptor-Deficient Mice
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
) mice.
The mortality resulting from Plasmodium berghei ANKA infection was delayed in uPA
/
and uPAR
/
mice but was similar to that of the wild type (+/+) in
tPA
/
mice. Parasitemia levels were similar in
uPA
/
, uPAR
/
, and +/+ mice. Production
of tumor necrosis factor, as judged from the plasma level and the mRNA
levels in brain and lung, was markedly increased by infection in both
+/+ and uPAR
/
mice. Breakdown of the blood-brain
barrier, as evidenced by the leakage of Evans Blue, was similar in +/+
and uPAR
/
mice. SM was associated with a profound
thrombocytopenia, which was attenuated in uPA
/
and
uPAR
/
mice. Administration of aprotinin, a plasmin
antagonist, also delayed mortality and attenuated thrombocytopenia.
Platelet trapping in cerebral venules or alveolar capillaries was
evident in +/+ mice but absent in uPAR
/
mice. In
contrast, macrophage sequestration in cerebral venules or alveolar
capillaries was evident in both +/+ and uPAR
/
mice.
Polymorphonuclear leukocyte sequestration in alveolar capillaries was
similar in +/+ and uPAR
/
mice. These results
demonstrate that the uPAR deficiency attenuates the severity of SM,
probably by its important role in platelet kinetics and trapping. These
results therefore suggest that platelet sequestration contributes to
the pathogenesis of SM.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2-integrin determinant) or in ICAM-1-deficient mice
(11, 12, 18).
2 integrin is expressed on leukocytes and is a ligand
for ICAM-1, which is widely distributed. Recent evidence indicates that
the function of
2 and other integrins is modulated by
the urokinase plasminogen activator receptor (uPAR; CD87) (reviewed in
reference 4). The uPAR is a 55-kDa
glycosylphosphatidylinositol (GPI)-linked surface receptor known to
bind urokinase plasminogen activator (uPA), plasminogen activator
inhibitor 1 (PAI-1), and vitronectin. Binding of uPA or PAI-1 to uPAR
is believed to influence the conformation of the uPAR and its
interaction with the integrin. Thus, the binding of uPA to the uPAR
might, on one hand, increase the generation of plasmin on the cell
surface and, on the other hand, increase the affinity or function of
the
2 integrin. In vivo, the traffic of PMNs in the
mouse peritoneum has been shown to be delayed in uPAR
/
mice (32).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
, tPA
/
, and
uPAR
/
genetically deficient mice
(uPAR
/
), isolated on the C57BL/6 × 129 background
(3, 8), were obtained from Carmeliet (Leuven, Belgium) and
bred in our animal house. Wild-type (+/+) controls were either C57BL/6J
or (C57BL/6 × 129)F1.
4. Platelets (4 × 109 to 10 × 109) were incubated at room temperature in ACD,
supplemented with mouse plasma (1%) and with 51Cr (0.1 mCi; The Radiochemical Center, Amersham, United Kingdom) for 2 h.
Platelets were then washed in ACD and counted. In different experiments, the labeling obtained ranged from 0.2 to 1 cpm/platelet, depending upon the age of the 51Cr batch. Platelets were
diluted with NaCl in order to inject (i.v.) 5 × 104
to 10 × 104 cpm in 0.1 ml in the retroorbital sinus
of the recipient mice.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
and in uPAR
/
mice (Fig.
1). In tPA
/
mice,
mortality was similar to that observed in +/+ recipients (not shown).
These results indicate that the uPA-uPAR system contributes to
mortality induced by the malarial infection. These genetic deficiencies
had no influence on the mortality observed 15 days after infection,
which is due to a severe anemia.

View larger version (18K):
[in a new window]
FIG. 1.
Survival of P. berghei ANKA (PbA)-infected
mice. (A) Survival of +/+ and uPAR
/
mice after
infection. Results were pooled from three experiments (n = 20, P < 0.04). (B) Survival of +/+ and uPA
/
mice after infection (n = 10, P < 0.05). (C)
Survival of infected +/+ mice treated from day 6 with aprotinin or BSA
as a control at 500 µg/day (difference between the groups:
n = 10, P < 0.05).
Effect of uPAR on parasitemia and thrombocytopenia associated with
SM.
Parasitemia was similar in +/+, uPAR
/
(Fig.
2) and uPA
/
mice (not
shown), suggesting that this system has no major influence on the early
diffusion of the parasite and also that parasitemia is not closely
related to mortality. Infection of +/+ mice induced a thrombocytopenia
which became profound when mice died, ca. day 7 to 8 days after
infection (Fig. 2). In uPAR mice, thrombocytopenia was markedly
attenuated (Fig. 2). Thrombocytopenia was also significantly (P < 0.05) attenuated in uPA
/
mice; on
day 8, the platelet counts were 6.5 (±2.4) × 105 and
9.5 (±1.7) × 105/µl for infected +/+ and
uPA
/
mice, respectively (mean ± the standard
deviation [SD]; n = 7).
|
Effect of aprotinin on mortality and thrombocytopenia associated with SM. uPA and uPAR are likely to contribute to enhance the activity of plasmin, a protease of broad specificity. Plasmin can be neutralized by the naturally occurring antagonist aprotinin (42). The administration of aprotinin, started on day 6, also decreased the mortality associated with the P. berghei ANKA infection (Fig. 1C). ANKA infection-induced thrombocytopenia was also significantly (P < 0.05) attenuated by aprotinin; the platelet counts were of 5.1 (±1.8) × 105 and 7.2 (±1.5) × 105/µl for bovine serum albumin (BSA)- and aprotinin-treated mice, respectively (n = 10).
Effect of malarial infection and uPAR on platelet kinetics.
The thrombocytopenia induced by ANKA infection is due in a large part
to a decrease in platelet survival (21). We transferred labeled platelets from +/+ or uPAR
/
donors to identical
recipients, either normal or infected, and investigated their survival
(Fig. 3). In +/+ recipients, the survival of +/+ platelets was markedly reduced by the infection, as reported previously (21). In contrast, the survival of
uPAR
/
platelets in a uPAR
/
host was
only slightly reduced by the infection. However, the platelet life span
in noninfected mice was markedly decreased in UPAR
/
mice, an observation described in more detail elsewhere
(38). Comparison between infected +/+ and
uPAR
/
mice showed only a slight reduction in life span
with platelets from uPAR
/
mice, indicating that the
infection in uPAR
/
mice does not decrease platelet life
span much more than is already the case in noninfected
uPAR
/
mice. This raises the possibility that ANKA
infection and uPAR deficiency decrease platelet life span by similar,
nonadditive mechanisms.
|
Effect of malarial infection and uPAR on fibrinogen clearance.
We examined the role of the uPAR in the clearance of labeled fibrinogen
in normal or infected mice. Malarial infection slightly, but
significantly, reduced the survival of labeled fibrinogen in +/+ mice,
while in uPAR
/
mice the survival of fibrinogen was not
modified by infection (Fig. 4). In
noninfected mice the clearance of fibrinogen was significantly
prolonged in uPAR
/
mice compared to +/+ mice (Fig. 4).
|
/
mice (not shown).
Effect of uPAR and malarial infection on spleen and lung
weight.
Malarial infection led to a massive lymphoproliferative
syndrome, resulting in a two- to threefold increase in the size of the
lymphoid organs after 7 days. As seen in Fig.
5, the increase was more pronounced in
uPAR
/
mice than in +/+ mice, indicating that the
attenuation of the disease in uPAR
/
mice is not due to
a decrease of lymphoproliferation. The lung weight was significantly
increased by infection in +/+ mice but not in uPAR
/
mice, suggesting that uPAR deficiency attenuates the pulmonary component of SM.
|
Effect of uPAR on the TNF mRNA levels.
The TNF mRNA levels
were examined in lung, brain, and spleen tissue from normal or infected
+/+ and uPAR
/
mice. As seen in Fig. 5, the mRNAs levels
were markedly increased by the P. berghei ANKA infection in
the lung and spleen, without a significant difference between infected
+/+ and uPAR
/
mice. The values are expressed as the
amount of TNF mRNA per microgram of RNA and do not take into account
the increase in size of the organs, i.e., they underestimate the amount
of mRNA/organ or mRNA/mouse. In the brain, the levels were about
fivefold lower than in the spleen, and there was no difference between
+/+ and uPAR
/
animals (not shown).
Effect of uPAR on the breakdown of the blood-brain and blood-lung
barriers (Evans Blue).
SM was associated with an increase of the
leakage of Evans Blue, which was especially evident in the brain and
lung. Under these present conditions, we did not detect a marked
difference between infected +/+ and uPAR
/
mice (data
not shown). Localization of labeled fibrinogen was also examined (see
above), and localization was similar in infected +/+ and
uPAR
/
mice (not shown).
Effect of uPAR on cell sequestration in alveolar capillaries.
An involvement of the lung was made evident by the lung weight, which
was significantly increased by the infection in +/+ mice (Fig. 5). As
seen by light microscopy, the infection resulted in a thickening of the
alveolar septa as reported previously (46), which was
evident in both infected +/+ and uPAR
/
mice (data not
shown). The variety of the cells trapped was examined in more detail by
semiquantitative electron microscopy (Fig.
6). Infection increased the number of
macrophages, PMNs, pRBC, and platelets within the alveolar capillaries.
In uPAR
/
mice, platelet trapping was markedly
decreased, while PMN and macrophage sequestration was slightly, but not
significantly, decreased. The percentage of pRBC in the alveolar
capillaries was increased by ca. 25%, compared to 5 to 10% in the
orbital sinus (Fig. 2 and 6), suggesting that the adherence of pRBC in the alveolar capillaries is also increased. This pRBC sequestration was
similar in +/+ and uPAR
/
mice (Fig. 6).
|
Platelet sequestration in the brain venules: evaluation by
immunohistochemistry.
In the brain, SM induced a sequestration of
macrophages in the cortical venules, which was evident by light
microscopy on sections stained with hematoxylin and eosin. Macrophage
sequestration was seen in both +/+ and uPAR
/
infected mice.
/
mice (Fig. 7E). These data were analyzed by
quantitative image analysis. As shown in Fig.
8, the intensity of GPIIb/IIIa staining normalized for the surface of individual vessels was significantly lower in uPAR
/
than in +/+ mice (4.3 ± 1.2 versus
33.3 ± 3.7 AU, respectively; n = 37 vessels
analyzed in four distinct mice; Mann-Whitney, P < 0.0001). This staining pattern of brain vessels from noninfected mice was similar to those of infected uPAR
/
mice (data
not shown). In contrast, sequestration of mononuclear leukocytes was
not significantly reduced in infected uPAR
/
mice
compared to +/+ mice (Fig. 8).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present report we provide evidence that uPA, in relation to the uPAR (CD87), contributes to the mortality of P. berghei ANKA infection, probably by its influence on platelet sequestration.
The uPA-uPAR deficiency, as well as the treatment with aprotinin, might
modify several systems implicated in the generation of the lethal
syndrome, such as the immune response, the parasitemia, the generation
of plasmin, and cell adhesion. There is no indication that uPAR
deficiency decreased the immune response. The increase in the size of
the lymphoid organs, induced by the infection, was not decreased in
uPAR
/
mice (and was, in fact, significantly increased
[see Fig. 5]), and the increase in TNF production was similar in +/+
and uPAR
/
mice. The treatment with aprotinin, a plasmin
inhibitor, which was effective when given immediately before the
syndrome, also argues that uPA-uPAR is involved in the effector and not
in the sensitization phase of the disease. A study in vitro has raised the possibility that plasmodia might use uPA to infect RBC
(41), but in the present study no important differences in
parasitemia appeared among +/+, uPA
/
, and
uPAR
/
mice that would support such a possibility.
Activation of the uPA-uPAR system might increase the generation of
plasmin and, consequently, proteolysis within the plasma. As judged
from the plasmatic fibrinogen, uPAR deficiency slightly increased, and malaria slightly decreased, the fibrinogen half-life. These
observations are in accord with previous reports indicating that a
coagulopathy is unlikely to be an important pathogenic mechanism in SM
(45) and that the uPA-uPAR system is therefore unlikely to
act at this level. Thus, these results favor the possibility that the
main effect of the uPA-uPAR is exerted on cell adhesion rather than on
extracellular proteolysis. This interpretation is also consistent with
the fact that tPA deficiency, which is not believed to influence adhesion, had no effect on mortality.
Mortality in SM in both humans and mice is associated with a breakdown
of the blood-brain barrier, but whether this is really an important
factor in the lethality is controversial (6). This increase
in vascular permeability is not closely correlated with macrophage
sequestration in the brain venules, since treatment with anti-CD11a MAb
or PMN depletion attenuate the breakdown of the blood-brain barrier
without decreasing macrophage sequestration in the brain
(46). The uPA-uPAR system had little influence on the
breakdown of the blood-brain barrier, suggesting that it is only one of
the factors which contributes to lethality. TNF might be responsible
for the increase in the vascular permeability, and the fact that
uPAR
/
mice did not show a decrease in TNF mRNA levels
is in accord with this possibility.
The uPA-uPAR system has been reported to modulate the function of
2 and other integrins (47) and, consequently,
the adhesion of leukocytes, i.e., PMNs and macrophages. A critical role
of
2 integrin in ANKA-induced mortality was demonstrated
by the lifesaving effect of anti-CD11a MAb (11, 18),
apparently by decreasing PMN sequestration in the lung (46).
The most obvious effect of mouse P. berghei ANKA infection
is to increase the sequestration of macrophages, which are apparently
activated by the phagocytosis of malarial pigment, in venules and
alveolar capillaries. In the brain and lung, uPAR did not increase, or
increased only slightly, macrophage trapping. PMN trapping is evident
in the alveolar capillaries, and this was not decreased in
uPAR-deficient mice. In mouse SM, sequestration of pRBC is important in
the alveolar capillaries and was decreased in ICAM-1-deficient mice
(12) but not in uPAR-deficient mice. Thus, uPAR deficiency
had only a moderate or insignificant influence on the sequestration of
PMNs, macrophages, or pRBC in the lung or brain. In another study uPAR
deficiency has been shown to moderately decrease PMN transmigration in
the mouse peritoneum (32).
By far, the most profound effect of uPAR deficiency was exerted on
platelet kinetics. Mouse or human SM is associated with thrombocytopenia, which appears relatively shortly before death (reviewed in reference 49). Thrombocytopenia was
markedly attenuated in uPA
/
and uPAR
/
mice, as well as in aprotinin-treated mice and, as suggested by Fig. 1
and 2, the extent of thrombocytopenia is a reliable indicator of the
forthcoming death. Since one of the effects of TNF is to produce
thrombocytopenia and platelet trapping (48), this
interpretation is consistent with evidence in both humans and mice
indicating that the lethality of malaria is correlated with TNF
production (15, 16, 31). Interestingly, malarial infection
or TNF injection did induce thrombocytopenia without coagulopathy
(45).
Thrombocytopenia is in large part due to a reduced life span of
platelets, resulting from a sequestration in various organs, such as
the brain, lung, and spleen (14). During SM, platelets appear to bind either to the activated endothelium or as a
cosequestration with macrophages, both of which are evident in brain
venules or alveolar capillaries and without fibrin deposition. Since
platelets are known to disintegrate quickly once activated, it is
likely that the semiquantitative evaluations performed by either
electron microscopy or immunohistochemistry underestimate the dynamic
process of platelet sequestration. A process of platelet disintegration is suggested in the brain by the diffusion of the immunoreactive material outside the blood vessels. In primates, localization of
platelet in brain venules, detected by staining with an anti-GPIIb/IIIa MAb, has also been reported during SM (13). Studies of the
lung and brain demonstrate that platelet trapping does not occur in uPAR
/
mice. Since uPAR is widely distributed,
interpretation of these results might be complex. In a recent study, we
presented evidence that uPAR is detectable on platelets and that
labeled platelets from uPAR
/
mice, injected into +/+
recipients, are unable to respond to an injection of TNF, suggesting
that it is indeed the platelet uPAR which is important for their
localization in response to TNF (30). Since uPAR deficiency
does not affect hemostasis or coagulation (8), these
findings further emphasize the selective effect of uPAR on platelet
kinetics and also suggest that platelet trapping, but not coagulation,
contributes to the pathogenesis of SM.
In various models of diseases, platelets have been reported to either
attenuate or aggravate inflammation (24, 30). The role of
platelets in inflammation (i.e., in the absence of hemostasis) is,
however, still difficult to delineate. This is in part because platelet
depletion experiments, which have been extensively used in the past,
elicit hemorrhages which prevent the study of inflammation. Platelets,
because of their rich content in mediators, such as transforming growth
factor
, interleukin-1, chemokines, BDNF, PAI-1, CD40L, etc.
(23, 25, 35, 40), can modulate the function (including the
state of activation and survival) of a wide variety of cells implicated
in SM, notably, endothelial cells, leukocytes, and neurones. Especially
intriguing is the mechanism by which platelets might deliver their
content. There are suggestions that this might happen either via
microparticles released in circulation (2) or by a process
of membrane fusion with the target cells, which has been suggested by
morphological observations (33, 39). Thus, in the present
study, we observed both direct platelet-endothelium interactions,
suggesting that platelets might activate endothelial cells (or promote
their apoptosis), or platelet-macrophage interactions, raising the
possibility that platelets contribute to the activation or adhesion of
circulating leukocytes. In support of this latter possibility,
platelet-dependent lymphocyte trapping has been recently reported
(9). However, in infected uPAR
/
mice,
macrophage sequestration was to a large extent preserved in spite of
markedly reduced platelet sequestration.
In both mice and humans, numerous pathogenic mechanisms have been associated with the mortality of SM, raising the possibility that different types of pathogenic events might contribute to the severity of the disease. Thus, the present results indicate that, without excluding other pathogenic processes, the uPA-uPAR system is a contributor to the severity of malaria, probably by its selective influence on platelet kinetics and trapping. Platelet sequestration in brain or elsewhere may therefore be one of the factors contributing to the gravity of the acute phase of malarial infection.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant 32-47284.96 from the Swiss National Science Foundation.
We are grateful to D. Männel (Regensburg, Germany) for providing the anti-GPIIb/IIIa MAb MWReg30 and to C. Allasia and H. Lepidi (Marseille, France) for their help in computerized image analysis.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathology, 1 rue M. Servet, SMU, 1211 Geneva, Switzerland. Phone: 41-22-70-25-758. Fax: 41-22-70-25-746. E-mail: pierre.piguet{at}medecine.unige.ch.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Barazzone, C.,
S. Horowitz,
Y. Donati,
C. Vesin,
A. Rochat,
I. Rodriguez, and P. F. Piguet.
1998.
Oxygen toxicity in mouse lung: pathways to cell death.
Am. J. Respir. Cell Mol. Biol.
19:573-581 |
| 2. | Barry, O. P., D. Pratico, J. A. Lawson, and G. A. Fitzgerald. 1997. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J. Clin. Investig. 99:2118-2127[Medline]. |
| 3. |
Bugge, T. H.,
T. T. Suh,
M. J. Flick,
C. C. Daugherty,
J. Romer,
H. Solberg,
V. Ellis,
K. Dano, and J. L. Degen.
1995.
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility.
J. Biol. Chem.
270:16886-16894 |
| 4. | Chapman, H. A. 1997. Plasminogen activators, integrins and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9:714-724[CrossRef][Medline]. |
| 5. |
Charoenpan, P.,
S. Indraprasit,
S. Kiatboonsri,
O. Suvachttanont, and S. Tanomsup.
1990.
Pulmonary oedema in severe falciparum malaria. Hemodynamic study and clinicophysiologic correlation.
Chest
97:1190-1197 |
| 6. | Clark, I. A., J. D. Macmicking, K. M. Gray, K. A. Rockett, and W. B. Cowden. 1992. Malaria mimicry with tumor necrosis factor. Contrasts between species of murine malaria and Plasmodium falciparum. Am. J. Pathol. 140:325-336[Abstract]. |
| 7. | Coquelin, F., Y. Boulard, E. Mora-Silvera, F. Richard, A. G. Chabaud, and I. Landau. 1999. Final stage maturation of the erythrocytic schizonts of rodent Plasmodium in the lungs. C. R. Acad. Sci. (III). 322:55-62[Medline]. |
| 8. | Dewerchin, M., A. Van Nuffelen, G. Wallays, A. Bouché, L. Moons, and P. Carmeliet. 1996. Generation and characterization of urokinase receptor-deficient mice. J. Clin. Investig. 97:870-878[Medline]. |
| 9. |
Diacovo, T. G.,
M. D. Catalina,
M. H. Siegelman, and U. H. von Andrian.
1998.
Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice.
J. Exp. Med.
187:197-204 |
| 10. | Duarte, M. I. S., C. E. P. Corbett, M. Boulos, and A. Neto. 1985. Ultrastructure of the lung in falciparum malaria. Am. J. Trop. Med. Hyg. 34:31-35. |
| 11. | Falanga, P. B., and E. C. Butcher. 1991. Late treatment with anti-LFA-1(CD11a) antibody prevents cerebral malaria in a mouse model. Eur. J. Immunol. 21:2259-2263[Medline]. |
| 12. | Favre, N., K. Willimann, B. Ryffel, N. Weiss, B. A. Imhof, W. Rudin, R. Lucas, and P. F. Piguet. 1999. Role of ICAM-1 in the development of murine cerebral malaria. Microbes Infect. 1:961-968[CrossRef][Medline]. |
| 13. | Fujioka, H., P. Millet, Y. Maeno, S. Nakazawa, Y. Ito, R. J. Howard, W. E. Collins, and M. Aikawa. 1994. A nonhuman primate model for human cerebral malaria: rhesus monkeys experimentally infected with Plasmodium fragile. Exp. Parasitol. 78:371-376[CrossRef][Medline]. |
| 14. | Grau, G. E., F. Tacchini-Cottier, C. Vesin, G. Milon, J. N. Lou, P. F. Piguet, and P. Juillard. 1993. TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/ICAM-1 interaction. Eur. Cyto. Net. 4:415-419[Medline]. |
| 15. |
Grau, G. E.,
L. F. Fajardo,
P. F. Piguet,
B. Allet,
P. H. Lambert, and P. Vassalli.
1987.
Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria.
Science
237:1210-1212 |
| 16. | Grau, G. E., T. Taylor, M. E. Molyneux, J. J. Wirima, P. Vassalli, M. Hommel, and P. H. Lambert. 1989. Tumor necrosis factor and disease severity in children with falciparum malaria. New. Engl. J. Med. 24:1586-1591. |
| 17. | Grau, G. E., D. Gretener, and P. H. Lambert. 1987. Prevention of murine cerebral malaria by low-dose cyclosporin A. Immunology 61:521-525[Medline]. |
| 18. | Grau, G. E., P. Pointaire, P. F. Piguet, C. Vesin, H. Rosen, I. Stamenkovic, F. Takei, and P. Vassalli. 1991. Late administration of monoclonal antibody to leukocyte function antigen 1 abrogates incipient murine cerebral malaria. Eur. J. Immunol. 21:2265-2267[Medline]. |
| 19. | Grau, G. E., P. F. Piguet, H. D. Engers, J. A. Louis, P. Vassalli, and P. H. Lambert. 1986. L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria. J. Immunol. 137:2348-2354[Abstract]. |
| 20. |
Grau, G. E.,
H. Heremans,
P. F. Piguet,
P. Pointaire,
P. H. Lambert,
A. Billiau, and P. Vassalli.
1989.
Monoclonal antibody against interferon-gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor.
Proc. Natl. Acad. Sci. USA
86:5572-5574 |
| 21. | Grau, G. E., P. F. Piguet, D. Gretener, C. Vesin, and P. H. Lambert. 1988. Immunopathology of thrombocytopenia in experimental malaria. Immunology. 65:501-506[Medline]. |
| 22. | Grau, G. E., and S. de Kossodo. 1994. Cerebral malaria: mediators, mechanical obstruction or more? Parasitol. Today 10:408-409[CrossRef][Medline]. |
| 23. |
Hawrylowicz, C. M.,
G. L. Howells, and M. Feldmann.
1991.
Platelet-derived interleukin-1 induces human endothelial adhesion molecules expression and cytokine production.
J. Exp. Med.
174:785-790 |
| 24. | Heffner, J. E., and J. E. Repine. 1997. Platelets, p. 947-960. In R. G. Crystal, J. B. West, E. R. Weibel, and P. J. Barnes (ed.), The lung: scientific foundations. Lippincott-Raven, Philadelphia, Pa. |
| 25. | Henn, V., J. R. Slupsky, M. Grafe, I. Anagnostopoulos, R. Forster, G. Mueller-Berghaus, and R. Kroczek. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591-594[CrossRef][Medline]. |
| 26. | Imhof, B. A., and D. Dunon. 1995. Leukocyte migration and adhesion. Adv. Immunol. 58:345-416[Medline]. |
| 27. | Lucas, R., J. N. Lou, P. Juillard, M. Moore, H. Bluethmann, and G. E. Grau. 1997. Respective role of TNF receptors in the development of experimental cerebral malaria. J. Neuroimmunol. 72:143-148[CrossRef][Medline]. |
| 28. | MacPherson, G. G., M. J. Warrell, N. J. White, S. Looareesuwan, and D. A. Warrell. 1985. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am. J. Pathol. 119:385-401[Abstract]. |
| 29. | Mann, H. B., and D. R. Whitney. 1947. On a test of whether one or two random variables is stochastically larger than the other. Ann. Math Statist. 18:50-60. |
| 30. |
Maennel, D., and G. E. Grau.
1997.
Role of platelet adhesion in homeostasis and immunopathology.
J. Clin. Pathol. Mol. Pathol.
50:175-185 |
| 31. | McGuire, W., V. S. Hill, C. E. M. Allsopp, B. M. Greewood, and D. Kwjatkowski. 1994. Variation in the TNF-a promoter region associated with susceptibility to cerebral malaria. Nature 371:508-511[CrossRef][Medline]. |
| 32. |
May, A. E.,
S. M. Kanse,
L. R. Lund,
R. H. Gisler,
B. A. Imhof, and K. T. Preissner.
1998.
Urokinase receptor (CD87) regulates leukocyte recruitment via beta-2 integrins in vivo.
J. Exp. Med.
188:1029-1037 |
| 33. | Nakamura, M., M. Shibazaki, Y. Nitta, and Y. Endo. 1998. Translocation of platelets into Disse spaces and their entry into hepatocytes in response to lipopolysaccharides, interleukin-1 and tumor necrosis factor: the role of Kupffer cells. J. Hepatol. 28:991-999[CrossRef][Medline]. |
| 34. |
Nieswandt, B.,
B. Echtenacher,
F. P. Wachs,
J. Schroder,
J. E. Gessner,
R. E. Schmidt,
G. E. Grau, and D. N. Mannel.
1999.
Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice.
Blood
94:684-693 |
| 35. | Nordenhem, A., and B. Wiman. 1997. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene. Scand. J. Clin. Lab. Investig. 57:453-461[Medline]. |
| 36. | Patnaik, J. K., B. S. Das, S. K. Mishra, S. Mohanty, S. K. Sapathy, and D. Mohanty. 1994. Vascular clogging, mononuclear cell margination, and enhanced vascular permeability in the pathogenesis of human cerebral malaria. Am. J. Trop. Med. Hyg. 51:642-647. |
| 37. |
Piguet, P. F.,
M. A. Collart,
G. E. Grau,
Y. Kapanci, and P. Vassalli.
1989.
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.
J. Exp. Med.
170:655-663 |
| 38. | Piguet, P. F., C. Vesin, C. D. Laperousaz, and A. Rochat. 2000. Role of plasminogen activators and of urokinase receptor (uPAR, CD87) in platelet kinetics in mice. J. Hematol., in press. |
| 39. |
Piguet, P. F.,
C. Vesin,
Y. Donati,
F. Tacchini-Cottier,
D. Belin, and C. Barazzone.
1999.
Urokinase-receptor (uPAR, CD87) is a platelet receptor important for kinetics and TNF-induced endothelial adhesion in mice.
Circulation
99:3315-3321 |
| 40. | Pliego Rivero, F. B., N. Bayatti, X. Giannakoulopoulos, V. Glover, H. F. Bradford, G. Stern, and M. Sandler. 1997. Brain-derived neurotrophic factor in human platelets. Biochem. Pharmacol. 54:207-209[CrossRef][Medline]. |
| 41. | Roggwiller, E., A. C. Fricaud, T. Blisnick, and C. Braun Breton. 1997. Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes. Mol. Biochem. Parasitol. 86:49-59[CrossRef][Medline]. |
| 42. | Royston, B. D., D. Royston, and J. D. Pearson. 1992. Aprotinin inhibits platelet adhesion to endothelial cells. Blood Coag. Fibrin. 3:737-742[Medline]. |
| 43. | Rudin, W., H. P. Eugster, G. Bordmann, J. Bonato, M. Muller, M. Yamage, and B. Ryffel. 1997. Resistance to cerebral malaria in tumor necrosis factor-alpha/beta-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am. J. Pathol. 150:257-266[Abstract]. |
| 44. |
Schofield, L., and F. Hackett.
1993.
Signal transduction in host cells by a glycosylphatidylinositol toxin of malaria parasites.
J. Exp. Med.
177:145-153 |
| 45. | Senaldi, G., and P. F. Piguet. 1998. Mortality and platelet depletion occur independently of fibrinogen consumption in murine models of tumor necrosis factor-mediated systemic inflammatory responses. Cytokine 10:382-389[CrossRef][Medline]. |
| 46. |
Senaldi, G.,
C. Vesin,
R. Chang,
G. Grau, and P. F. Piguet.
1994.
An effector role of neutrophils in the pathogenesis of murine severe malaria.
Infect. Immun.
62:1144-1149 |
| 47. | Sitrin, R. G., R. F. Todd III, H. R. Petty, T. G. Brock, S. B. Shollenberger, E. Albrecht, and M. R. Gyetko. 1996. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J. Clin. Investig. 97:1942-1951[Medline]. |
| 48. |
Tacchini-Cottier, F.,
C. Vesin,
M. Redard,
W. Buurman, and P. F. Piguet.
1998.
Role of TNF receptors I and II in TNF-induced platelets consumption in mice.
J. Immunol.
160:6182-6186 |
| 49. | White, N. J., and M. Ho. 1992. The pathophysiology of malaria, p. 84-173. Academic Press, Inc., New York, N.Y. |
| 50. | World Health Organization Malaria Action Programme. 1986. Severe and complicated malaria. Trans. R. Soc. Trop. Med. Hyg. 80:3-50. |
| 51. | Wright, D. H. 1968. The effect of neonatal thymectomy on the survival of golden hamsters infected with Plasmodium berghei. Br. J. Exp. Pathol. 49:379-384[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»